Diarrhea and Constipation Drug Development Pipeline Review, 2018

SKU ID :GBI-12161745 | Published Date: 30-Jul-2018 | No. of pages: 93
Diarrhea and Constipation Drug Development Pipeline Review, 2018

Summary

This report provides an overview of the pipeline landscape for diarrhea and constipation. It provides comprehensive information on the therapeutics under development and key players involved in therapeutic development for diarrhea and constipation, and features dormant and discontinued products.

Diarrhea is a contagious gastrointestinal infection occurring mostly due to unhygienic conditions. Diarrhea may be related to a viral or bacterial infection and is sometimes the result of food poisoning. Symptoms include nausea, abdominal pain, cramping, bloating, dehydration, fever, bloody stools, frequent urge to evacuate the bowels and incontinence. There are 54 products in development for this indication and molecular targets present in the pipeline landscape include cystic fibrosis transmembrane conductance regulator and glucagon like peptide 2 receptor.

Constipation refers to the infrequent or difficult passing of stool. Constipation occurs when bowel movements become difficult or less frequent. Symptoms of constipation include swollen abdomen or abdominal pain, pain and vomiting.

The predisposing factors include eating disorders, irritable bowel syndrome, and hypothyroidism, overuse of laxatives (stool softeners) which, over time, weaken the bowel muscles, stress, inadequate water intake and inadequate fiber in the diet. There are 25 products in development for this indication and molecular targets present in the pipeline landscape include 5-hydroxytryptamine receptor 4 and heat stable enterotoxin receptor.

Companies operating in this pipeline space include Synthetic Biologics, Allergan and Ardelyx.

Scope

- Which companies are the most active within each pipeline?
- Which pharmaceutical approaches are the most prominent at each stage of the pipeline and within each indication?
- To what extent do universities and institutions play a role within this pipeline, compared to pharmaceutical companies?
- What are the most important R&D milestones and data publications to have happened in this disease area?

Reasons to buy

- Understand the overall pipeline, with an at-a-glance overview of all products in therapeutic development for each indication
- Assess the products in development in granular detail, with an up-to-date overview of each individual pipeline program in each indication and a comprehensive picture of recent updates and milestones for each
- Analyze the companies, institutions and universities currently operating in the pipeline and the products being fielded by each of these
- Understand the composition of the pipeline in terms of molecule type, molecular target, mechanism of action and route of administration
  • PRICE
  • $3995
    $11985
    Buy Now

Our Clients